Soumaia Sayed RAMMADAN, Faizeh AL-QUOBAİLİ

Increased serum cholesteryl ester transfer protein in Syrian obese humans

Amaç: Obez kişilerde serum kolesterol ester transfer proteininin (CETP), artmış ve aterojenik lipoporotein profili ile ilişkili olup olmadığının belirlenmesidir. Yöntemler: Gece boyu süren açlık sonrası 102 bireyden (76 obez, 26 sağlıklı kontrol) sabah kanı alınmıştır. Aynı zamanda bu bireylerde boy, vücut ağırlığı, bel çevresini içeren antropometrik ölçümler de yapılmıştır. Serumdaki CETP aktivitesi, floresan yöntemle, total kolesterol (TC), trigliserid, HDL-kolesterol, LDL-kolesterol ve glukoz düzeyleri enzimatik kolorimetrik testle ve insülin düzeyi ise ELISA ile ölçülmüştür. Bulgular: Serum CETP aktivitesi obez grupta kontrol grubuna göre belirgin şekilde yüksek olarak saptandı (58.15 ± 12.24 karşılık 47.75 ± 7.54 pmol/μl/1 saat, ortalama ± standart hata, p

Suriyeli obez bireylerde artmış serum kolesterol ester transfer protein düzeyleri

Objective: To determine whether serum cholesteryl ester transfer protein(CETP), is increased and associated with atherogenic lipoprotein profile in obese subjects. Methods: Blood was drawn in the morning after an overnight fast from 102 subjects (76 obese subjects and 26 apparently healthy subjects as control group) and, at the same time, anthropometric measurements including height, body weight, waist girth were taken. CETP activity were measured in serum using fluorescence assay, whereas total cholesterol (TC), triglyceride, HDL-cholesterol, LDL-cholesterol and Glucose levels were measured using enzymatic colorimetric assay and insulin was measured using ELISA. Results: Serum CETP activity was significantly higher (58.15 ± 12.24 vs. 47.75 ± 7.54 pmol/μl/1hr, means ± SEM, p < 0.0001) in the obese group than in the control group. There was considering direct relation for CETP activity with BMI, TC, and LDL-C (p

PDF

___

1.Barter P, Brewer H, Chapman M, Hennekens C, Rader D, Tall A. Cholesteryl Ester Transfer Protein. A Novel Target for Raising HDL and Inhibiting Atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 160-7.
2. Rühling K, Lang A, Richard F, Van Tol A, Eisele B, Herzberg V, et al. Net mass transfer of plasma cholesteryl esters and lipid transfer proteins in normolipidemic patients with peripheral vascular disease. Metabolism 1999; 48: 13616.
3. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998; 338: 8693.
4.Sugano M, Sawada S, Tsuchida K, Makino N, Kamada M. Low density lipoproteins develop resistance to oxidative modification due to inhibition of cholesteryl ester transfer protein by a monoclonal antibody. J Lipid Res 2000; 41: 12633.
5.Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406: 203-7.
6.de Grooth G, Klerkx A, Stroes E, Stalenhoef A, Kastelein J and Kuivenhoven J. A review of CETP and its relation to atherosclerosis. J Lipid Res 2004; 45: 1967-74.
7.Stevenson CG. Cholesterol ester transfer protein: a molecule with three faces? Crit Rev Clin Lab Sci 1998; 35:51746.
8. St. Peter J, Billington C. Obesity. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic approach. 7th ed. New York, NY: Mc-Graw-Hill, 2008:2442.
9.MacLean P, Bower J, Vadlamudi S, Green T, Barakat H. Lipoprotein subpopulation distributions in lean, obese, and type 2 diabetic women: a comparison of African and white Americans. Obes Res 2000; 8: 6270.
10.Hayashibe H, Asayama K, Nakane T, Uchida N, Kawada Y, Nakazawa S. Increased plasma cholesteryl ester transfer activity in obese children. Atherosclerosis 1997;129:538.
11.Riemens SC, van Tol A, Sluiter WJ, Dullaart RP. Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese type II diabetic patients. Diabetologia 1998; 41:92934.
12. Arai T, Yamashita S, Hirano K, Sakai N, Kotani K, Fujioka S, et al. Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb 1994;14:1129-36.
13.Birjmohun R, Hutten B, Kastelein J and Stroes E. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45: 185-97.
14. Goldberg A, Alagona P Jr, Capuzzi DM, Guyton J, Morgan JM, Rodgers J, et al. Multiple-dose efficacy and safety of an extendedrelease form of niacin in the management of hyperlipidemia. Am J Cardiol 2000; 85:1100-5.
15. Asayama K, Hayashibe H, Dobashi K, Uchida N, Nakane T, Kodera K, et al. Increased serum cholesteryl ester transfer protein in obese children. Obes Res 2002;10:43946.
16.MacLean P, Vadlamudi S, MacDonald K, Pories W and Barakat H. Suppression of hepatic cholesteryl ester transfer protein expression in obese humans with the development of type 2 diabetes mellitus. J Clin Endocrinol Metab 2005; 90: 2250-8.
17.Bruce C, Chouinard Jr R, Tall A. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr 1998;18:297330.
18.Arii K, Suehiro T, Yamamoto M, Ito H, Hashimoto K. Suppression of plasma cholesteryl ester transfer protein activity in acute hyperinsulinemia and effect of plasma nonesterified fatty acid. Metabolism 1997; 46:116670.
19. Kaser S, Föger B, Ebenbichler CF, Kirchmair R, Gander R, Ritsch A, et al. Influence of leptin and insulin on lipid transfer proteins in human hepatoma cell line, HepG2.Int J Obes Relat Metab Disord 2001; 25:163-9.
20. Berti JA, Casquero AC, Patricio PR, Bighetti EJ, Carneiro EM, Boschero AC, et al.Cholesteryl ester transfer protein expression is down-regulated in hyperinsulinemic transgenic mice. J Lipid Res 2003; 44:1870-6.
21.Cheema S, and Rashid-Kolvear F. Streptozotocin-induced increase in cholesterol ester transfer protein (CETP) and its reversal by insulin in transgenic mice expressing human CETP. Can J Physiol Pharmacol 2003; 81:9971004
22. Geltner C, Lechleitner M, Foger B, Ritsch A, Drexel H, Patsch J. Insulin improves fasting and postprandial lipemia in type 2 diabetes. Eur J Intern Med 2002; 13:25663.
23.Ai M, Tanaka A, Baba T, Yui K, Numano F. Increased cholesteryl ester transfer protein and changes in lipid metabolism from initiating insulin therapy. Ann NY Acad Sci 2001; 947:35661.
24.MacLean P, Vadlamudi S, MacDonald K, Pories W, Houmard J, Barakat H Impact of insulin resistance on lipoprotein subpopulation distribution in lean and morbidly obese nondiabetic women. Metabolism 2000; 49:28592.
25.Maclean P, Tanner C, Houmard J, Barakat H Plasma cholesteryl ester transfer protein activity is not linked to insulin sensitivity. Metabolism 2001; 50:7838.
26.Bagdade JD, Dunn FL, Eckel RH, Ritter MC Intraperitoneal insulin therapy corrects abnormalities in cholesteryl ester transfer and lipoprotein lipase activities in insulin- dependent diabetes mellitus. Arterioscler Thromb 1994;14:19339.
27.de Grooth G, Smilde T, van Wissen S, Klerkx A, Zwinderman A, Fruchart J, Kastelein J, Stalenhoef A, and Kuivenhoven J. The relationship between cholesteryl ester transfer protein levels and risk factors in patients with familial hypercholesterolemia. Atherosclerosis 2004;173: 261-7.
28.Van Tol A. CETP-catalysed transfer of cholesterylesters from HDL to apo B- containing lipoproteins in plasma from diabetic patients. Eur J Clin Invest 1993;23:856.
29.Luo Y, and Tall A. Sterol up regulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 2000;105: 513-20.
30.Richardson MA, Berg DT, Johnston PA, McClure D, Grinnell BW. Human liposarcoma cell line, SW872, secretes cholesteryl ester transfer protein in response to cholesterol. J Lipid Res 1996;37:1162-6.